Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (31): 5773-5777.doi: 10.3969/j.issn.1673-8225.2010.31.018

Previous Articles     Next Articles

Comparative study between off-pump and on-pump coronary artery bypass grafting: A Meta-analysis

Zhao Yan, Pan Jun, Wang Dong-jin   

  1. Department of Cardio-thoracic Surgery, Drum Tower Clinical College, Nanjing Medical University, Nanjing  210008, Jiangsu Province, China
  • Online:2010-07-30 Published:2010-07-30
  • Contact: Professor, Master’s supervisor, Department of Cardio-thoracic Surgery, Drum Tower Clinical College, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China Yzhao2002@yahoo.cn
  • About author:Zhao Yan, Studying for maser’s degree, Department of Cardio-thoracic Surgery, Drum Tower Clinical College, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China

PDF

400

Abstract:

BACKGROUND: Studies demonstrated that the living quality of patients had no significant differences following off-pump (OPCAB) or on-pump coronary artery bypass grafting (CCAB). The decrease of living quality related to graft lesions and arrhythmia.
OBJECTIVE: To evaluate whether OPCAB is superior to conventional CCAB.
METHODS: The comparative studies regarding therapeutic effects of OPCAB and CCAB from 2000 to 2009 were searched, and collecting relevant data was Meta analyzed using RevMan 4.2 statistical software.
RESULTS AND CONCLUSION: A total 16 documents were included in this study, including 1 392 cases in the OPCAB group and 1 252 cases in the CCAB group. Results of Meta analysis demonstrated that, OPCAB was superior to CCAB in ICU duration, ventilation time, hospitalization time, postoperative 24-hour drainage volume, and postoperative complications (P < 0.05), but the graft number was lower than that of the CCAB group (P < 0.05). However, the age had no difference between the two groups   (P > 0.05). The results revealed that compared with CCAB, OPCAB receives superior short term outcome in the treatment of coronary artery disease, but the long term effectiveness needs to be explored.

CLC Number: